AI Engines For more Details: Perplexity Kagi Labs You
Gallstone Dissolution: Chenodiol works by reducing the production of cholesterol in the liver and decreasing the secretion of cholesterol into bile. By doing so, it can help dissolve cholesterol gallstones, which are the most common type of gallstones found in the gallbladder. Chenodiol therapy may take several months to achieve complete dissolution of gallstones.
Cholelithiasis: Chenodiol is indicated for the treatment of cholelithiasis, a condition characterized by the presence of gallstones in the gallbladder or bile ducts. It is specifically effective for dissolving cholesterol gallstones but may not be suitable for other types of gallstones, such as pigment stones.
Prevention of Gallstone Formation: In some cases, chenodiol may be used as a preventive measure to reduce the recurrence of gallstones in individuals who are at high risk of developing them, such as those with a history of gallstone formation or certain metabolic disorders predisposing them to gallstone formation.
Side Effects: Common side effects of chenodiol may include diarrhea, abdominal discomfort, nausea, vomiting, and changes in liver function tests. These side effects are usually mild and transient but may necessitate dose adjustments or discontinuation of therapy in some cases.
Contraindications: Chenodiol is contraindicated in individuals with known hypersensitivity to the drug, those with acute inflammation of the gallbladder or bile ducts, and those with complete obstruction of the bile ducts. It should be used with caution in individuals with liver or kidney impairment.
Monitoring: During treatment with chenodiol, patients typically undergo regular monitoring of liver function tests and imaging studies to assess the effectiveness of gallstone dissolution and detect any potential complications, such as obstruction of the bile ducts.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | -0.3 | |
| ADHD | 4 | 4 | |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 1.1 | |
| Allergic Rhinitis (Hay Fever) | 2.4 | 2.5 | -0.04 |
| Allergies | 5.1 | 3.2 | 0.59 |
| Allergy to milk products | 1.9 | 1.2 | 0.58 |
| Alopecia (Hair Loss) | 1 | 1 | |
| Alzheimer's disease | 4.8 | 5 | -0.04 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.4 | 1.1 | 2.09 |
| Ankylosing spondylitis | 3.6 | 1.2 | 2 |
| Anorexia Nervosa | 1.2 | 2.4 | -1 |
| Antiphospholipid syndrome (APS) | 0.6 | 0.6 | |
| Asthma | 4.5 | 3 | 0.5 |
| Atherosclerosis | 1.8 | 1.7 | 0.06 |
| Atrial fibrillation | 2.5 | 1.2 | 1.08 |
| Autism | 6.3 | 7.1 | -0.13 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.1 | 1.1 | |
| Bipolar Disorder | 1.4 | 1.1 | 0.27 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 0.4 | 0.4 | |
| Cancer (General) | 0.9 | 2.3 | -1.56 |
| Carcinoma | 3.4 | 2.2 | 0.55 |
| Celiac Disease | 1.5 | 3.3 | -1.2 |
| Cerebral Palsy | 1.6 | 1.3 | 0.23 |
| Chronic Fatigue Syndrome | 3.9 | 3.9 | 0 |
| Chronic Kidney Disease | 3.2 | 1.8 | 0.78 |
| Chronic Lyme | 0.4 | 0.8 | -1 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.3 | 1.7 | -0.31 |
| Chronic Urticaria (Hives) | 1.7 | 0.5 | 2.4 |
| Coagulation / Micro clot triggering bacteria | 1.2 | 1.3 | -0.08 |
| Cognitive Function | 2.6 | 1.6 | 0.63 |
| Colorectal Cancer | 4.8 | 2 | 1.4 |
| Constipation | 1.5 | 0.7 | 1.14 |
| Coronary artery disease | 1.8 | 1.6 | 0.13 |
| COVID-19 | 7.2 | 8.1 | -0.13 |
| Crohn's Disease | 5.2 | 4.5 | 0.16 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.9 | 1.9 | -1.11 |
| d-lactic acidosis (one form of brain fog) | 0.4 | 0.4 | |
| deep vein thrombosis | 1.2 | 1.4 | -0.17 |
| Denture Wearers Oral Shifts | 0.9 | 0.9 | |
| Depression | 7.6 | 6.9 | 0.1 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.7 | 1.4 | 0.21 |
| Endometriosis | 2.5 | 2.1 | 0.19 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 3.1 | 1.4 | 1.21 |
| erectile dysfunction | 1.4 | 0.3 | 3.67 |
| Fibromyalgia | 1.8 | 1 | 0.8 |
| Functional constipation / chronic idiopathic constipation | 4.1 | 2.6 | 0.58 |
| gallstone disease (gsd) | 2.5 | 1.4 | 0.79 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.6 | 1.2 | -1 |
| Generalized anxiety disorder | 2.2 | 1.9 | 0.16 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.1 | 0.4 | 4.25 |
| Graves' disease | 1.5 | 3 | -1 |
| Gulf War Syndrome | 0.6 | 1 | -0.67 |
| Halitosis | 1.2 | 0.3 | 3 |
| Hashimoto's thyroiditis | 3.4 | 1.5 | 1.27 |
| Heart Failure | 2.9 | 1.5 | 0.93 |
| hemorrhagic stroke | 0.9 | 0.9 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 1.4 | 0.6 | 1.33 |
| hypercholesterolemia (High Cholesterol) | 0.8 | 0.5 | 0.6 |
| hyperglycemia | 2.1 | 1.4 | 0.5 |
| Hyperlipidemia (High Blood Fats) | 0.8 | 0.3 | 1.67 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 4.2 | 4.7 | -0.12 |
| Hypothyroidism | 0.7 | 0.4 | 0.75 |
| Hypoxia | 2.9 | 0.3 | 8.67 |
| IgA nephropathy (IgAN) | 1.2 | 3.2 | -1.67 |
| Inflammatory Bowel Disease | 5.2 | 6.9 | -0.33 |
| Insomnia | 1.6 | 2.8 | -0.75 |
| Intelligence | 1 | 1 | |
| Intracranial aneurysms | 1 | 0.3 | 2.33 |
| Irritable Bowel Syndrome | 6.2 | 4.3 | 0.44 |
| ischemic stroke | 2.5 | 1.4 | 0.79 |
| Liver Cirrhosis | 6 | 4.7 | 0.28 |
| Long COVID | 3.8 | 6.6 | -0.74 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 1 | 1.5 | -0.5 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.9 | 0.6 | 0.5 |
| ME/CFS with IBS | 0.6 | 1.7 | -1.83 |
| ME/CFS without IBS | 0.5 | 1.7 | -2.4 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2.1 | 0.8 | 1.63 |
| Metabolic Syndrome | 5.3 | 6.6 | -0.25 |
| Mood Disorders | 8 | 5.1 | 0.57 |
| multiple chemical sensitivity [MCS] | 0.8 | 0.1 | 7 |
| Multiple Sclerosis | 5.1 | 3.4 | 0.5 |
| Multiple system atrophy (MSA) | 1.5 | 0.7 | 1.14 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 3.1 | -3.1 | |
| Neuropathy (all types) | 0.7 | 1.8 | -1.57 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.9 | 0.9 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5.1 | 4.6 | 0.11 |
| NonCeliac Gluten Sensitivity | 1.5 | 0.6 | 1.5 |
| Obesity | 9.3 | 6.2 | 0.5 |
| obsessive-compulsive disorder | 4.5 | 2.7 | 0.67 |
| Osteoarthritis | 1.8 | 1.4 | 0.29 |
| Osteoporosis | 2.2 | 1.8 | 0.22 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 6.6 | 4.6 | 0.43 |
| Polycystic ovary syndrome | 4.1 | 3.1 | 0.32 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
| Premenstrual dysphoric disorder | 0.7 | 0.7 | |
| primary biliary cholangitis | 1.2 | 1.3 | -0.08 |
| Primary sclerosing cholangitis | 2.1 | 1.2 | 0.75 |
| Psoriasis | 2.9 | 1.3 | 1.23 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5.8 | 3.2 | 0.81 |
| Rosacea | 1 | 0.7 | 0.43 |
| Schizophrenia | 5.7 | 2.6 | 1.19 |
| scoliosis | 0.4 | 0.7 | -0.75 |
| Sjögren syndrome | 2.2 | 2.1 | 0.05 |
| Sleep Apnea | 1.9 | 1.3 | 0.46 |
| Slow gastric motility / Gastroparesis | 1.2 | 0.3 | 3 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.7 | 0.6 | 1.83 |
| Stress / posttraumatic stress disorder | 2.8 | 1.9 | 0.47 |
| Systemic Lupus Erythematosus | 2.9 | 2.2 | 0.32 |
| Tic Disorder | 0.9 | 1.2 | -0.33 |
| Tourette syndrome | 1.1 | 0.3 | 2.67 |
| Type 1 Diabetes | 3.2 | 3.8 | -0.19 |
| Type 2 Diabetes | 5.2 | 5.4 | -0.04 |
| Ulcerative colitis | 3.7 | 4.5 | -0.22 |
| Unhealthy Ageing | 2.7 | 1.4 | 0.93 |
| Vitiligo | 1.5 | 0.7 | 1.14 |
